A hot new migraine drug, positive financials, and several promising drug candidates in late-stage trials are luring investors to this stock.
News & Analysis: Biohaven Pharmaceutical Holding Company Ltd.
Dilution is coming for shareholders, while an acquisition doesn't seem as likely.
Rumor has it that the drugmaker is up for sale.
Biohaven announced a "successful achievement" that failed to impress investors.
A lead product candidate failed in a phase 2/3 trial, but shares have recovered to a smaller loss.